FORXIGA (AstraZeneca Pty Ltd)
Product name
FORXIGA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
177 (255 working days)
Active ingredients
dapagliflozin propanediol monohydrate
Registration type
EOI
Indication
Heart failure
FORXIGA is indicated in adults for the treatment of symptomatic heart failure independent of left ventricular ejection fraction, as an adjunct to standard of care therapy (see section 5.1 Pharmacodynamic properties).